HC Wainwright Reiterates “Buy” Rating for Keros Therapeutics (NASDAQ:KROS)

Keros Therapeutics (NASDAQ:KROS)‘s stock had its “buy” rating reissued by HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They presently have a $40.00 price objective on the stock. HC Wainwright’s price target would indicate a potential upside of 298.41% from the stock’s previous close.

A number of other brokerages have also recently issued reports on KROS. Oppenheimer lowered their price target on shares of Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating for the company in a research report on Thursday, January 16th. TD Cowen lowered shares of Keros Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Piper Sandler cut their price target on Keros Therapeutics from $40.00 to $15.00 and set an “overweight” rating on the stock in a research note on Friday, January 17th. BTIG Research lowered Keros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, December 12th. Finally, Wells Fargo & Company dropped their target price on Keros Therapeutics from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Thursday, February 27th. Six investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $42.33.

Keros Therapeutics Stock Performance

Keros Therapeutics stock opened at $10.04 on Tuesday. Keros Therapeutics has a fifty-two week low of $9.41 and a fifty-two week high of $72.37. The stock has a market cap of $407.24 million, a price-to-earnings ratio of -1.93 and a beta of 1.39. The stock’s 50 day simple moving average is $11.07 and its two-hundred day simple moving average is $33.47.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share for the quarter, beating the consensus estimate of ($1.36) by $0.22. The company had revenue of $3.04 million for the quarter, compared to analyst estimates of $37.32 million. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. On average, analysts predict that Keros Therapeutics will post -4.74 earnings per share for the current year.

Hedge Funds Weigh In On Keros Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. AlphaQuest LLC lifted its stake in shares of Keros Therapeutics by 469.0% in the 4th quarter. AlphaQuest LLC now owns 3,596 shares of the company’s stock worth $57,000 after purchasing an additional 2,964 shares during the period. Point72 Asia Singapore Pte. Ltd. increased its holdings in Keros Therapeutics by 36.7% during the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,844 shares of the company’s stock valued at $223,000 after buying an additional 1,033 shares during the last quarter. Virtus ETF Advisers LLC boosted its stake in shares of Keros Therapeutics by 107.5% during the 4th quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company’s stock worth $61,000 after acquiring an additional 1,998 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Keros Therapeutics by 59.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,371 shares of the company’s stock worth $312,000 after acquiring an additional 1,994 shares during the last quarter. Finally, KLP Kapitalforvaltning AS bought a new stake in shares of Keros Therapeutics during the 4th quarter valued at $90,000. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.